Videos

Treatment Options for HER2+ Breast Cancer After Progression on Tucatinib

Dr Stefania Maraka presents the case of a 53-year-old woman with de novo metastatic mutated ER/PR+ HER2+ breast cancer and brain metastases.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

Nicolas Girard, MD, on Future Research Efforts With Nivolumab and Chemotherapy in Resectable NSCLC

Experts discuss their choice of systemic therapies after a patient with metastatic HER2+ breast cancer and brain metastases progresses on tucatinib therapy.

Nicolas Girard, MD

Strategies and Barriers in mUC Maintenance Therapy

In a conversation with CancerNetwork®, Nicolas Girard, MD, highlighted directions of future research with nivolumab and chemotherapy in patients with resectable non–small cell lung cancer.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.

Brian I. Rini, MD;Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

The Exciting Future of Advanced Renal Cell Carcinoma Management

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

Marie Carlo, MD;Mehmet Asim Bilen, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

Unmet Needs in Advanced Renal Cell Carcinoma Management

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

Safety and Efficacy Data: The CheckMate 9ER Trial

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP

Safety and Efficacy Data: The KEYNOTE-426 Trial

Robert Alter, MD, reviews the CheckMate 9ER trial of cabozantinib/nivolumab versus sunitinib in advanced renal cell cancer.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP

Renal Cell Carcinoma: Future Directions in Care

Arnab Basu, MD, MPH, FACP discusses data from the KEYNOTE-426 trial of axitinib/pembrolizumab versus sunitinib in metastatic RCC.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

Treatment Strategies for Patients Who Progress on Adjuvant Pembrolizumab

Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

Daniel P. Petrylak, MD, Talks About Importance of Mentorships in Genitourinary Oncology

Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.

Daniel P. Petrylak, MD

Catherin Watson, MD, Discusses Designing a Trial on Genetic Testing Education in Ovarian Cancer

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, reflects upon mentorship during his training to become an oncologist.

Catherine Watson, MD

April 30th 2022

At SGO 2022, Catherine Watson, MD, spoke about the 2 arms of a randomized education trial presented at the conference.

Nicolas Girard, MD, on the Rationale and Design of the Phase 3 CheckMate 816 Trial in Resectable NSCLC

Nicolas Girard, MD

April 30th 2022

In an interview with CancerNetwork®, Nicolas Girard, MD, discussed the rationale for assessing nivolumab and chemotherapy in resectable non–small cell lung cancer and the design of the phase 3 CheckMate 816 trial.

Matthew Krebs, MB, PhD Discusses Phase 1 PALOMA Trial Results of Subcutaneous Amivantamab in Solid Tumors

Matthew Krebs, MB, PhD

Factors in Selecting Therapy for Non-Small Cell Lung Cancer

Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

Biomarker Testing Practices in Non-Small Cell Lung Cancer

Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

Stéphane Champiat, MD, PhD, Talks Benefits With and Next Steps for SOT101 and Pembrolizumab

Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.

Stéphane Champiat, MD, PhD

Newly Diagnosed Multiple Myeloma: The MASTER and GMMG-HD7 Trials

Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Frederick Locke, MD, Speaks to Clinicians on the Use of Axi-cel in LBCL

A review of the study design and results of two clinical trials researching quadruplet therapies for newly diagnosed multiple myeloma presented at ASH 2021.

Frederick Locke, MD

Emory Experts Discuss Multi-Agent Induction Regimens for Transplant-Eligible Newly Diagnosed Myeloma

Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

The Effect of Trial Design on Approval of GVHD Therapies

An overview of the currently available frontline treatment options for transplant-eligible multiple myeloma.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD